Phase III study of APF530 versus ondansetron with a neurokinin 1 antagonist plus corticosteroid in preventing highly emetogenic chemotherapy-induced nausea and vomiting: MAGIC trial.

被引：15
|
作者：
Schnadig, Ian D.
Agajanian, Richy
Dakhil, Shaker R.
Gabrail, Nashat Y.
Smith, Robert E.
Taylor, Charles W.
Wilks, Sharon
Cooper, William
Mosier, Michael
Payne, Yvette
Klepper, Michael
Vacirca, Jeffrey L.
机构：
[1] US Oncol Network, Compass Oncol, Tualatin, OR USA
[2] Oncol Inst Hope & Innovat, Whittier, CA USA
[3] Canc Ctr Kansas, Wichita, KS USA
[4] Gabrail Canc Ctr, Canton, OH USA
[5] South Carolina Oncol Associates, Columbia, SC USA
[6] Tulsa Canc Inst, Tulsa, OK USA
[7] Canc Care Ctr South Texas, San Antonio, TX USA
[8] TFS Int, Flemington, NJ USA
[9] EMB Stat Solut LLC, Overland Pk, KS USA
[10] Heron Therapeut Inc, San Diego, CA USA
[11] Drug Safety Navigator LLC, Durham, NC USA
[12] North Shore Hematol Oncol, East Setauket, NY USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 28期
关键词：
D O I：
10.1200/jco.2015.33.28_suppl.68
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
68
引用
收藏
页数：1
相关论文
共 50 条
  • [41] A phase III open-label study to assess safety and efficacy of palonosetron for preventing chemotherapy-induced nausea and vomiting (CINV) in repeated cycles of emetogenic chemotherapy
    Kenjiro Aogi
    Hiroshi Sakai
    Hirohisa Yoshizawa
    Norikazu Masuda
    Nobuyuki Katakami
    Yasuhiro Yanagita
    Kenichi Inoue
    Masaru Kuranami
    Mitsuhiro Mizutani
    Noriyuki Masuda
    Supportive Care in Cancer, 2012, 20 : 1507 - 1514
  • [42] Olanzapine with or without an NK-1 receptor antagonist for preventing chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy: A phase III randomized, double-blind, placebo-controlled trial (ALLIANCE A221602).
    Navari, Rudolph M.
    Le-Rademacher, Jennifer
    Smieliauskas, Fabrice
    Ruddy, Kathryn Jean
    Saphner, Thomas James
    Liu, Heshan
    Harlos, Beth
    Onitilo, Adedayo A.
    Giridhar, Karthik
    Singh, Preet Paul
    Reddy, Pavan S.
    Kruter, Flavio
    Raptis, George
    Loprinzi, Charles L.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [43] Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting (CINV): A randomized phase III trial
    Navari, R. M.
    Gray, S. E.
    Kerr, A. C.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [44] Phase 3 trial results for rolapitant, a novel NK-1 receptor antagonist, in the prevention of chemotherapy-induced nausea and vomiting (CINV) in subjects receiving highly emetogenic chemotherapy (HEC).
    Rapoport, Bernardo Leon
    Poma, Allen
    Hedley, Mary Lynne
    Martell, Robert E.
    Navari, Rudolph M.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [45] A randomized phase II study of aprepitant, ondansetron and dexamethasone for chemotherapy-induced nausea and vomiting in Chinese breast cancer patients receiving moderately emetogenic chemotherapy
    Yeo, W.
    Mo, F. K. F.
    Suen, J. J. S.
    Ho, W. M.
    Chan, S. L.
    Yeung, W. K.
    Lau, W.
    Lee, K. K. C.
    Kwan, W. H.
    Zee, B.
    EJC SUPPLEMENTS, 2008, 6 (07): : 198 - 198
  • [46] Steroid-free regimen with aprepitant in preventing chemotherapy-induced nausea and vomiting in patients with colorectal cancer receiving FOLFOX chemotherapy: A randomized phase III trial.
    Wang, Wenjing
    Ling, Jiayu
    Cai, Yue
    Zhang, Jianwei
    Hu, Huabin
    Li, Shanshan
    Xiao, Jian
    Deng, Yanhong
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [47] A phase III, randomized, double-blind study of single-dose intravenous fosaprepitant in preventing chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy
    Rapoport, Bernardo Leon
    Weinstein, Cindy
    Camacho, Elber S.
    Khanani, Saleem A.
    Beckford-Brathwaite, Elizabeth
    Kevill, Lydia
    Vallejos, Waldimir
    Liang, Li Wen
    Noga, Stephen Joseph
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [48] Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron
    Gralla, R
    Lichinitser, M
    Van der Vegt, S
    Sleeboom, H
    Mezger, J
    Peschel, C
    Tonini, G
    Labianca, R
    Macciocchi, A
    Aapro, M
    ANNALS OF ONCOLOGY, 2003, 14 (10) : 1570 - 1577
  • [49] Palonosetron (PALO) versus granisetron (GRA) in the triplet regimen with dexamethasone (DEX) and aprepitant (APR) for preventing chemotherapy-induced nausea and vomiting (CINV) in patients (pts) receiving highly emetogenic chemotherapy (HEC) with cisplatin (CDDP): A randomized, double-blind, phase III trial.
    Hashimoto, Hironobu
    Yamanaka, Takeharu
    Shimada, Yasuhiro
    Arata, Koji
    Matsui, Reiko
    Goto, Koichi
    Takiguchi, Tomomi
    Ohyanagi, Fumiyoshi
    Kogure, Yuki
    Nogami, Naoyuki
    Nakao, Masahiko
    Takeda, Koji
    Azuma, Kanako
    Nagase, Seisuke
    Hayashi, Toshinobu
    Fujiwara, Kimiko
    Shimada, Toshikazu
    Seki, Nobuhiko
    Suzuki, Kenichi
    Yamamoto, Nobuyuki
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [50] Neurokinin-1 Receptor Antagonist-Based Triple Regimens in Preventing Chemotherapy-Induced Nausea and Vomiting: A Network Meta-Analysis
    Zhang, Yaxiong
    Yang, Yunpeng
    Zhang, Zhonghan
    Fang, Wenfeng
    Kang, Shiyang
    Luo, Youli
    Sheng, Jin
    Zhan, Jianhua
    Hong, Shaodong
    Huang, Yan
    Zhou, Ningning
    Zhao, Hongyun
    Zhang, Li
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2017, 109 (02):
12345